Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis.

Détails

ID Serval
serval:BIB_B7ECE615E458
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis.
Périodique
European Journal of Pediatrics
Auteur(s)
Neuhaus T.J., Berger C., Buechner K., Parvex P., Bischoff G., Goetschel P., Husarik D., Willi U., Molinari L., Rudin C., Gervaix A., Hunziker U., Stocker S., Girardin E., Nadal D.
ISSN
1432-1076[electronic]
Statut éditorial
Publié
Date de publication
2008
Volume
167
Numéro
9
Pages
1037-1047
Langue
anglais
Résumé
The hypothesis was tested that oral antibiotic treatment in children with acute pyelonephritis and scintigraphy-documented lesions is equally as efficacious as sequential intravenous/oral therapy with respect to the incidence of renal scarring. A randomised multi-centre trial was conducted in 365 children aged 6 months to 16 years with bacterial growth in cultures from urine collected by catheter. The children were assigned to receive either oral ceftibuten (9 mg/kg once daily) for 14 days or intravenous ceftriaxone (50 mg/kg once daily) for 3 days followed by oral ceftibuten for 11 days. Only patients with lesions detected on acute-phase dimercaptosuccinic acid (DMSA) scintigraphy underwent follow-up scintigraphy. Efficacy was evaluated by the rate of renal scarring after 6 months on follow-up scintigraphy. Of 219 children with lesions on acute-phase scintigraphy, 152 completed the study; 80 (72 females, median age 2.2 years) were given ceftibuten and 72 (62 females, median age 1.6 years) were given ceftriaxone/ceftibuten. Patients in the intravenous/oral group had significantly higher C-reactive protein (CRP) concentrations at baseline and larger lesion(s) on acute-phase scintigraphy. Follow-up scintigraphy showed renal scarring in 21/80 children treated with ceftibuten and 33/72 with ceftriaxone/ceftibuten (p = 0.01). However, after adjustment for the confounding variables (CRP and size of acute-phase lesion), no significant difference was observed for renal scarring between the two groups (p = 0.2). Renal scarring correlated with the extent of the acute-phase lesion (r = 0.60, p < 0.0001) and the grade of vesico-ureteric reflux (r = 0.31, p = 0.03), and was more frequent in refluxing renal units (p = 0.04). The majority of patients, i.e. 44 in the oral group and 47 in the intravenous/oral group, were managed as out-patients. Side effects were not observed. From this study, we can conclude that once-daily oral ceftibuten for 14 days yielded comparable results to sequential ceftriaxone/ceftibuten treatment in children aged 6 months to 16 years with DMSA-documented acute pyelonephritis and it allowed out-patient management in the majority of these children.
Mots-clé
Administration, Oral, Adolescent, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/therapeutic use, Ceftriaxone/administration & dosage, Ceftriaxone/therapeutic use, Cephalosporins/administration & dosage, Cephalosporins/therapeutic use, Child, Child, Preschool, Drug Administration Schedule, Female, Humans, Infant, Injections, Intravenous, Male, Pyelonephritis/drug therapy, Pyelonephritis/pathology, Technetium Tc 99m Dimercaptosuccinic Acid
Pubmed
Web of science
Création de la notice
12/01/2010 9:56
Dernière modification de la notice
20/08/2019 15:26
Données d'usage